Critical roles of Sp1 in gene expression of human and rat H +/organic cation antiporter MATE1

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 5, 2007, Pages

  Kajiwara, Moto ^a   Terada, Tomohiro ^a   Asaka, Jun Ichi ^a   Ogasawara, Ken ^a   Katsura, Toshiya ^a   Ogawa, Osamu ^a   Fukatsu, Atsushi ^a   Doi, Toshio ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Basal transcriptional activity; Multidrug and toxin extrusion 1; Single nucleotide polymorphism; Tubular secretion

Indexed keywords

ANTIPORTER; CIMETIDINE; MITHRAMYCIN; MULTIDRUG AND TOXIN EXTRUSION 1 PROTEIN; ORGANIC CATION TRANSPORTER; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 36048993190     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00322.2007     Document Type: Article

References (37)

1. Asaka J, Terada T, Okuda M, Katsura T, Inui K. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm Res 23: 697-704, 2006.
2. +/organic cation antiporter, multidrug and toxin extrusion (MATE). Mol Pharmacol 46: 1487-1493, 2007.
3. Blake MC, Jambou RC, Swick AG, Kahn JW, Azizkhan JC. Transcriptional initiation is controlled by upstream GC-box interactions in a TATAA-less promoter. Mol Cell Biol 10: 6632-6641, 1990.
4. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621, 1991.
5. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195: 27-38, 2002.
6. Buckland PR. The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762: 17-28, 2006.
7. Burckhardt G, Wolff NA. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 278: F853-F866, 2000.
8. Douet V, Heller MB, Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem Biophys Res Commun 354: 66-71, 2007.
9. 1. J Pharmacol Exp Ther 252: 286-292, 1990.
10. Fujii G, Nakamura Y, Tsukamoto D, Ito M, Shiba T, Takamatsu N. CpG methylation at the USF-binding site is important for the liver-specific transcription of the chipmunk HP-27 gene. Biochem J 395: 203-209, 2006.
11. Grant SFA, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I α1 gene. Nat Genet 14: 203-205, 1996.
12. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372: 549-552, 1994.
13. Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K. Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Ann NY Acad Sci 1086: 223-232, 2006.
14. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58: 944-958, 2000.
15. 1. Biochem J 227: 199-203, 1985.
16. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79: 427-439, 2006.
17. +-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1. Am J Physiol Gastrointest Liver Physiol 278: G591-G603, 2000.
18. Mastrangelo IA, Courey AJ, Wall JS, Jackson SP, Hough PVC. DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement. Proc Natl Acad Sci USA 88: 5670-5674, 1991.
19. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17: 2127-2135, 2006.
20. Nishihara K, Masuda S, Ji L, Katsura T, Inui K. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochem Pharmacol 73: 1482-1490, 2007.
21. Nomura J, Hisatsune A, Miyata T, Isohoma Y. The role of CpG methylation in cell type-specific expression of the aquaporin-5 gene. Biochem Biophys Res Commun 353: 1017-1022, 2007.
22. Ogasawara K, Terada T, Asaka J, Katsura T, Inui K. Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney. Am J Physiol Renal Physiol 292: F1819-F1826, 2007.
23. Ohta K, Inoue K, Hayashi Y, Yuasa H. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H antiporter in the kidney. Drug Metab Dispos 34: 1868-1874, 2006.
24. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W, Hashiramoto M, Kanatsuka A, Fujii Y, Ohashi J, Makino H. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75: 678-686, 2004.
25. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102: 17923-17928, 2005.
26. Pugh BF, Tjian R. Transcription from a TATA-less promoter requires a multisubunit TFIID complex. Genes Dev 5: 1935-1945, 1991.
27. Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest 83: 2003-2007, 1989.
28. Saito H, Yamamoto M, Inui K, Hori R. Transcellular transport of organic cation across monolayers of kidney epithelial cell line LLC-PK1. Am J Physiol Cell Physiol 262: C59-C66, 1992.
29. Shimakura J, Terada T, Katsura T, Inui K. Characterization of the human peptide transporter PEPT1 promoter: Sp1 functions as a basal transcriptional regulator of human PEPT1. Am J Physiol Gastrointest Liver Physiol 289: G471-G477, 2005.
30. Shimakura J, Terada T, Shimada Y, Katsura T, Inui K. The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochem Pharmacol 71: 1581-1588, 2006.
31. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. In press.
32. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117: 1422-1431, 2007.
33. +-organic cation antiporters. Biochem Pharmacol 74: 359-371, 2007.
34. +/organic cation antiporter MATE1. Pharm Res 23: 1696-1701, 2006.
35. +/organic cation antiporter MATE1. Am J Physiol Renal Physiol 292: F593-F598, 2007.
36. Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol 204: 309-319, 2005.
37. Zhang X, Cherrington NJ, Wright SH. Molecular identification and functional characterization of rabbit MATE1 and MATE2-K. Am J Physiol Renal Physiol 293: F360-F370, 2007.